MX2016008448A - Var2csa-drug conjugates. - Google Patents

Var2csa-drug conjugates.

Info

Publication number
MX2016008448A
MX2016008448A MX2016008448A MX2016008448A MX2016008448A MX 2016008448 A MX2016008448 A MX 2016008448A MX 2016008448 A MX2016008448 A MX 2016008448A MX 2016008448 A MX2016008448 A MX 2016008448A MX 2016008448 A MX2016008448 A MX 2016008448A
Authority
MX
Mexico
Prior art keywords
var2csa
drug conjugates
conjugates
disclosed
drug
Prior art date
Application number
MX2016008448A
Other languages
Spanish (es)
Inventor
Babcook John
John Hedberg Bradley
R Rich James
EL-SALANTI Ali
DAUGAARD Mads
Dahlback Madeleine
Original Assignee
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Inc filed Critical Zymeworks Inc
Publication of MX2016008448A publication Critical patent/MX2016008448A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.
MX2016008448A 2013-12-27 2014-12-29 Var2csa-drug conjugates. MX2016008448A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361921242P 2013-12-27 2013-12-27
US201462051899P 2014-09-17 2014-09-17
US201462051886P 2014-09-17 2014-09-17
PCT/CA2014/000919 WO2015095952A1 (en) 2013-12-27 2014-12-29 Var2csa-drug conjugates

Publications (1)

Publication Number Publication Date
MX2016008448A true MX2016008448A (en) 2017-01-09

Family

ID=53477241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008448A MX2016008448A (en) 2013-12-27 2014-12-29 Var2csa-drug conjugates.

Country Status (12)

Country Link
US (1) US10675355B2 (en)
EP (1) EP3087091B1 (en)
JP (1) JP6615115B2 (en)
KR (1) KR20160125361A (en)
CN (1) CN106459162A (en)
AU (1) AU2014373640B2 (en)
BR (1) BR112016015105A8 (en)
CA (1) CA2935064C (en)
MX (1) MX2016008448A (en)
RU (1) RU2714933C2 (en)
SG (1) SG11201605260VA (en)
WO (1) WO2015095952A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2968440T (en) * 2013-03-15 2019-07-31 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
ES2916722T3 (en) 2013-12-27 2022-07-05 Zymeworks Inc Sulfonamide-containing linkage systems for drug conjugates
MX2016008448A (en) 2013-12-27 2017-01-09 Zymeworks Inc Var2csa-drug conjugates.
IL287645B2 (en) 2014-09-17 2024-04-01 Zymeworks Bc Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
PL3250237T3 (en) 2015-01-30 2021-12-13 Sutro Biopharma, Inc. Hemiasterlin derivatives for conjugation and therapy
EP3413920A1 (en) * 2016-02-08 2018-12-19 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
CN109069658B (en) 2016-02-08 2022-10-14 西纳福克斯股份有限公司 Antibody-conjugates with improved therapeutic index for targeting HER2 tumors and methods for improving the therapeutic index of antibody-conjugates
EP3413922A1 (en) * 2016-02-08 2018-12-19 SynAffix B.V. Improved sulfamide linkers for use in bioconjugates
US9840481B2 (en) 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
CN106512022B (en) * 2016-10-12 2019-09-27 广东艾时代生物科技有限责任公司 Hydroxyl radical carthamin yellow carthamus A-red blood cell sticks chondroitin sulfate A (CSA) receptor protein polypeptide compound in the application for preparing anti-tumor drug
DK3666787T3 (en) 2017-08-10 2024-03-11 Sumitomo Pharma Co Ltd ANTIBODIAL DRUG CONJUGATES INCLUDING HEMIASTERN DERIVATIVES
EP4321523A3 (en) 2017-08-10 2024-04-24 Sumitomo Pharma Co., Ltd. Hemiasterlin derivatives and antibody-drug conjugates including same
CN108570118B (en) * 2017-10-17 2020-07-03 中国科学院深圳先进技术研究院 Affinity chromatography purification method of placenta-like chondroitin sulfate A or derivative thereof
GB2585607B (en) * 2017-11-29 2022-09-07 Cas Lamvac Guangzhou Biomedical Tech Co Ltd Chimeric antigen receptor and application thereof
CN113412271A (en) 2019-02-13 2021-09-17 大日本住友制药株式会社 Hamiltrin derivatives having cysteine residue
CN110124045A (en) * 2019-04-30 2019-08-16 云南大学 Application of the plasmodium VAR2CSA albumen in anti-tumor drug
CN113952467A (en) * 2020-07-21 2022-01-21 深圳先进技术研究院 Endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof
WO2023118150A1 (en) 2021-12-22 2023-06-29 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium.

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
AU679479B2 (en) 1992-12-16 1997-07-03 Basf Aktiengesellschaft Dolostatin analog
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
CA2225325A1 (en) 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP1531846A4 (en) 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
NZ535139A (en) * 2002-03-22 2007-07-27 Eisai Co Ltd Hemiasterlin derivatives and uses thereof in the treatment of cancer
US7064211B2 (en) 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
CA2483725A1 (en) 2002-04-23 2003-11-06 Ohio State University Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin
ITMI20021391A1 (en) 2002-06-25 2003-12-29 Nicox Sa NITRO-DERIVATIVES OF CYCLOOXYGENASE-2 INHIBITORS
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1539682A2 (en) 2002-09-20 2005-06-15 Wyeth Holdings Corporation Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors
US20040121965A1 (en) 2002-09-20 2004-06-24 Wyeth Holdings Corporation Method of treating resistant tumors
AU2003295808A1 (en) 2002-11-21 2004-06-18 Wyeth Hemiasterlin affinity probes and their uses
US7390910B2 (en) 2003-08-08 2008-06-24 Wyeth Compounds for treating tumors
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CA2538829A1 (en) 2003-09-15 2005-03-24 The University Of British Columbia Ceratamines a and b, and analogues, syntheses and pharmaceutical compositions thereof
ATE459364T1 (en) 2003-10-22 2010-03-15 Univ Johns Hopkins IMPROVED BACTERIOLYSIS COMBINATION THERAPY FOR THE TREATMENT OF TUMORS
BR122018071968B8 (en) 2003-11-06 2021-07-27 Seattle Genetics Inc antibody-drug conjugate, pharmaceutical composition, article of manufacture and use of an antibody-drug conjugate
US7078562B2 (en) 2004-01-19 2006-07-18 Mitsubishi Gas Chemical Company, Inc. Adamantane derivatives and resin compositions using the same as raw material
AU2005281359A1 (en) * 2004-08-26 2006-03-16 Apparao Satyam Prodrugs and codrugs containing novel bio-cleavable disulfide linkers
WO2006039652A2 (en) * 2004-09-30 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chondroitin sulfate a binding domains
EP3505191A1 (en) 2004-11-12 2019-07-03 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
EP2722051B1 (en) 2005-07-07 2018-11-07 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
CN104016970A (en) 2007-10-10 2014-09-03 诺华股份有限公司 Spiropyrrolidines and their use against HCV and HIV infection
US20090155289A1 (en) 2007-11-01 2009-06-18 Steve Roberts Furin-cleavable peptide linkers for drug-ligand conjugates
EP2245054B1 (en) 2008-01-30 2018-11-28 Pieris Pharmaceuticals GmbH Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same
EP2842575B1 (en) 2008-03-18 2017-09-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
PL2865387T3 (en) * 2008-11-21 2019-12-31 Københavns Universitet (University Of Copenhagen) Priming of an immune response
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
TW201117809A (en) 2009-09-25 2011-06-01 Astellas Pharma Inc Substituted amide compounds
EP2579887B1 (en) 2010-06-10 2014-11-12 Seattle Genetics, Inc. Novel auristatin derivatives and use thereof
FR2963241B1 (en) * 2010-07-30 2014-10-24 Inst Rech Developpement Ird VACCINE AGAINST GESTATIONAL MALARIA
ES2537726T3 (en) 2010-09-24 2015-06-11 Astellas Pharma Inc. Substituted amide compound
PL2678037T3 (en) 2011-02-25 2015-05-29 Lonza Ag Branched linker for protein drug conjugates
WO2012123957A1 (en) 2011-03-16 2012-09-20 Council Of Scientific & Industrial Research Oligopeptides and process for preparation thereof
WO2012135440A1 (en) 2011-03-30 2012-10-04 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
CN103826661B (en) 2011-04-21 2019-03-05 西雅图基因公司 New bonding agent-drug conjugate (ADC) and application thereof
US20130190248A1 (en) 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
KR101733853B1 (en) 2011-11-17 2017-05-08 화이자 인코포레이티드 Cytotoxic peptides and antibody drug conjugates thereof
US11787844B2 (en) * 2012-02-09 2023-10-17 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
EP3925627A1 (en) 2012-05-15 2021-12-22 Concortis Biosystems, Corp Drug-conjugates and uses thereof
AU2013270686B2 (en) 2012-06-07 2016-11-10 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
EP2861262B1 (en) 2012-06-19 2018-11-28 Ambrx, Inc. Anti-cd70 antibody drug conjugates
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
JP6133431B2 (en) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Use of hydrophilic conjugates and conjugation reactions between drug molecules and cell binding molecules
SG11201504887TA (en) 2012-12-21 2015-07-30 Bioalliance Cv Hydrophilic self-immolative linkers and conjugates thereof
WO2014126836A1 (en) 2013-02-14 2014-08-21 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
PT2968440T (en) 2013-03-15 2019-07-31 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
CA2934030A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
CA2930614A1 (en) 2013-12-17 2015-06-25 Novartis Ag Cytotoxic peptides and conjugates thereof
MX2016008448A (en) 2013-12-27 2017-01-09 Zymeworks Inc Var2csa-drug conjugates.
ES2916722T3 (en) 2013-12-27 2022-07-05 Zymeworks Inc Sulfonamide-containing linkage systems for drug conjugates
IL287645B2 (en) 2014-09-17 2024-04-01 Zymeworks Bc Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules

Also Published As

Publication number Publication date
CA2935064A1 (en) 2015-07-02
WO2015095952A1 (en) 2015-07-02
CA2935064C (en) 2023-06-27
SG11201605260VA (en) 2016-07-28
US20170246310A1 (en) 2017-08-31
CN106459162A (en) 2017-02-22
EP3087091A4 (en) 2017-06-14
BR112016015105A2 (en) 2017-09-19
US10675355B2 (en) 2020-06-09
KR20160125361A (en) 2016-10-31
BR112016015105A8 (en) 2018-04-24
US20180117163A9 (en) 2018-05-03
RU2016130348A (en) 2018-01-31
RU2714933C2 (en) 2020-02-21
JP2017505335A (en) 2017-02-16
AU2014373640A1 (en) 2016-07-07
JP6615115B2 (en) 2019-12-04
RU2016130348A3 (en) 2018-08-06
AU2014373640B2 (en) 2018-08-30
EP3087091B1 (en) 2021-10-20
EP3087091A1 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
MX2016008448A (en) Var2csa-drug conjugates.
PH12019500176A1 (en) Heterocyclic compounds and ther uses
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2015009106A (en) Solid solution compositions and use in severe pain.
MX2017004838A (en) Interleukin-15 compositions and uses thereof.
NZ711982A (en) Cytotoxic and anti-mitotic compounds, and methods of using the same
GB201106750D0 (en) Novel compounds
TN2015000411A1 (en) Ceftolozane antibiotic compositions
MX359769B (en) Methods of decellularizing bone.
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
TR201910866T4 (en) Combined preparations for cancer treatment.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX367393B (en) ANTIFUNGAL COMPOSITIONS FOR THE TREATMENT OF SKIN and NAILS.
MX2017012596A (en) A pharmaceutical composition and the use thereof.
MX2019015527A (en) Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance.
EP3071214A4 (en) Salacia compositions, methods of treatment by their administration, and methods of their preparation
MX2015016603A (en) Corticosteroid compositions.
MX367773B (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof.
MX345263B (en) Stable pexiganan formulation.
PH12017501979A1 (en) Pharmaceutical compound